Taletrectinib in ROS1+ non-small cell lung cancer: a cost-effectiveness analysis in the United States.
Saved in:
| Title: | Taletrectinib in ROS1+ non-small cell lung cancer: a cost-effectiveness analysis in the United States. |
|---|---|
| Authors: | Huo G; Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China., Wang X; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China., Song Y; Department of Pharmacy, Jining NO.1 People's Hospital, Jining, Shandong, China., Tian Y; Medical Insurance Office, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China., Chen P; Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China. |
| Source: | Frontiers in pharmacology [Front Pharmacol] 2026 Apr 13; Vol. 17, pp. 1684603. Date of Electronic Publication: 2026 Apr 13 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1663-9812 |
|---|---|
| DOI: | 10.3389/fphar.2026.1684603 |
